Guideline for Evaluation and Management of Recurrent Vaginal Symptoms

Diagnostic Evaluation

• Immediate re‑evaluation with vaginal pH measurement, saline + KOH wet‑mount microscopy, and a vaginal culture with yeast speciation is recommended when initial point‑of‑care tests are negative and an inappropriate antibiotic (e.g., nitrofurantoin) has been given. – CDC 1, 2, 3

• Interpretation of vaginal pH:

  • pH ≤ 4.5 supports vulvovaginal candidiasis (VVC).
  • pH > 4.5 supports bacterial vaginosis (BV) or trichomoniasis. – CDC 1, 2, 4

• Wet‑mount microscopy protocol:

  • Saline preparation – assess for motile trichomonads, clue cells (BV), and white blood cells. – CDC 5, 6
  • 10 % KOH preparation – enhances visualization of yeast/pseudohyphae and enables the “whiff test” (fishy amine odor) for BV or trichomoniasis. – CDC 1, 2, 7

Laboratory Test Performance

• Microscopy sensitivity for candidiasis is only ~57 % and fails to detect 40–50 % of infections; therefore, culture or molecular testing is needed for accurate diagnosis. – CDC 7, Clinical Infectious Diseases 3

• Vaginal culture with speciation is the gold standard for diagnosing VVC and other infections; results are available in 48–72 h. – Clinical Infectious Diseases 3, CDC 8

• PCR (molecular) testing for Candida groups shows superior accuracy (sensitivity ≈ 90.9 %, specificity ≈ 94.1 %) compared with microscopy (sensitivity ≈ 57.5 %, specificity ≈ 89.4 %). – Clinical Infectious Diseases 3

Microbiologic Considerations

• Non‑albicans Candida species, especially Candida glabrata, account for ~10–20 % of VVC cases and are frequently azole‑resistant. – Clinical Infectious Diseases 8

• Short‑course over‑the‑counter azole regimens (1–3 days) are inadequate for non‑albicans VVC; longer courses (7–14 days) are required for complicated or severe disease. – Clinical Infectious Diseases 8

• Trichomoniasis must be excluded in recurrent discharge; wet‑mount has a high false‑negative rate, so culture or DNA‑probe testing is recommended. – CDC 9, 10

• Bacterial vaginosis diagnosis requires ≥ 3 of 4 Amsel criteria:

Treatment Recommendations

• If culture confirms Candida albicans:

  • Fluconazole 150 mg orally as a single dose or topical azole for 7 days. – CDC 1, Clinical Infectious Diseases 3

• If culture confirms Candida glabrata (azole‑resistant):

  • Boric acid 600 mg intravaginal gelatin capsules daily for 14 days (pharmacy‑compounded). – Clinical Infectious Diseases 8
  • Nystatin 100,000 U vaginal tablet daily for 14 days. – CDC 1, Clinical Infectious Diseases 8
  • Consider compounded 17 % flucytosine cream ± 3 % amphotericin B cream for refractory cases. – Clinical Infectious Diseases 8

• If bacterial vaginosis is confirmed:

  • Metronidazole 500 mg orally twice daily for 7 days. – CDC 7, 11
  • Alternatives: Metronidazole 0.75 % intravaginal gel for 5 days or clindamycin 2 % intravaginal cream for 7 days. – CDC 7, 11

• If trichomoniasis is confirmed:

  • Metronidazole 2 g orally as a single dose or 500 mg orally twice daily for 7 days. – CDC 9, 10
  • All sexual partners must receive concurrent treatment. – CDC 9, 10

Clinical Pitfalls & Safety

• Do not initiate empiric therapy or treat based solely on symptoms or visual appearance; objective testing is mandatory. – CDC 1, 2

• A positive vaginal culture for Candida in an asymptomatic woman (10–20 % prevalence) does not require treatment. – CDC 1, 2, 4

• Avoid using nitrofurantoin for any form of vaginitis; it has no efficacy for vaginal infections. – (excluded “ignore ref” statements)

• Reserve short‑course (1–3 day) antifungal regimens for uncomplicated, mild‑to‑moderate VVC; complicated or recurrent cases need extended (7–14 day) therapy. – CDC 2, 4

Therapeutic Strategies for Persistent Vaginal Candidiasis

Topical Azole Therapy (7–14 day Course)

• Topical azole agents (e.g., clotrimazole 1 % cream 5 g intravaginally daily or miconazole 2 % cream 5 g intravaginally daily for 7–14 days) are as effective as a single oral dose of fluconazole for uncomplicated vulvovaginal candidiasis and provide longer local drug exposure for complicated or severe infections. Evidence from a randomized controlled trial reported comparable clinical cure rates, supporting the use of topical therapy when extended local activity is desired. 12

Maintenance Suppressive Therapy for Recurrent Infection

• For women experiencing recurrent vulvovaginal candidiasis (defined as ≥ 4 episodes per year) caused by fluconazole‑susceptible Candida species, a suppressive regimen of fluconazole 150 mg taken orally once weekly for up to 6 months after achieving an initial cure is recommended. This strategy is supported by clinical trial data demonstrating reduced recurrence rates with weekly prophylaxis. 12